|
1
|
Huang J, Chan WC, Ngai CH, Lok V, Zhang L,
Lucero-Prisno DE III, Xu W, Zheng ZJ, Elcarte E, Withers M, et al:
Worldwide burden, risk factors, and temporal trends of ovarian
cancer: A global study. Cancers. 14(2230)2022.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Andreou M, Kyprianidou M, Cortas C,
Polycarpou I, Papamichael D, Kountourakis P and Giannakou K:
Prognostic factors influencing survival in ovarian cancer patients:
A 10-year retrospective study. Cancers (Basel).
15(5710)2023.PubMed/NCBI View Article : Google Scholar
|
|
3
|
International Agency for Research on
Cancer (IARC): Absolute numbers, Incidence and Mortality, Females,
in 2022. IARC, Lyon, 2022.
|
|
4
|
Akter S, Rahman MA, Hasan MN, Akhter H,
Noor P, Islam R, Shin Y, Rahman MDH, Gazi MS, Huda MN, et al:
Recent advances in ovarian cancer: Therapeutic strategies,
potential biomarkers, and technological improvements. Cells.
11(650)2022.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Momenimovahed Z, Tiznobaik A, Taheri S and
Salehiniya H: Ovarian cancer in the world: Epidemiology and risk
factors. Int J Womens Health. 11:287–299. 2019.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Kurnit KC, Fleming GF and Lengyel E:
Updates and new options in advanced epithelial ovarian cancer
treatment. Obstet Gynecol. 137:108–121. 2021.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Menon U, Gentry-Maharaj A, Burnell M,
Singh N, Ryan A, Karpinskyj C, Carlino G, Taylor J, Massingham SK,
Raikou M, et al: Ovarian cancer population screening and mortality
after long-term follow-up in the UK Collaborative trial of ovarian
cancer screening (UKCTOCS): A randomised controlled trial. Lancet.
397:2182–2193. 2021.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Li Y, Cen Y, Tu M, Xiang Z, Tang S, Lu W,
Zhang H and Xu J: Nanoengineered gallium ion incorporated
formulation for safe and efficient reversal of PARP inhibition and
platinum resistance in ovarian cancer. Research (Wash D C).
6(0070)2023.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Goulding EA, Simcock B, McLachlan J, van
der Griend R and Sykes P: Low-grade serous ovarian carcinoma: A
comprehensive literature review. Aust N Z J Obstet Gynaecol.
60:27–33. 2020.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Darelius A, Kristjansdottir B, Dahm-Kähler
P and Strandell A: Risk of epithelial ovarian cancer Type I and II
after hysterectomy, salpingectomy and tubal ligation-A nationwide
case-control study. Int J Cancer. 149:1544–1552. 2021.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Pavlik EJ, Smith C, Dennis TS, Harvey E,
Huang B, Chen Q, Piecoro DW, Burgess BT, McDowell A, Gorski J, et
al: Disease-specific survival of type I and II epithelial ovarian
cancers-stage challenges categorical assignments of indolence &
aggressiveness. Diagnostics. 10(56)2020.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Wu N, Zhang X, Fang C, Zhu M, Wang Z, Jian
L, Tan W, Wang Y, Li H, Xu X, et al: Progesterone enhances
niraparib efficacy in ovarian cancer by promoting
palmitoleic-acid-mediated ferroptosis. Research (Wash D C).
7(0371)2024.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Grisham RN, Slomovitz BM, Andrews N,
Banerjee S, Brown J, Carey MS, Chui H, Coleman RL, Fader AN,
Gaillard S, et al: Low-grade serous ovarian cancer: Expert
consensus report on the state of the science. Int J Gynecol Cancer.
33:1331–1344. 2023.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Matsuo K, Machida H, Matsuzaki S, Grubbs
BH, Klar M, Roman LD, Sood AK, Gershenson DM and Wright JD:
Evolving population-based statistics for rare epithelial ovarian
cancers. Gynecol Oncol. 157:3–11. 2020.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Dey P, Nakayama K, Razia S, Ishikawa M,
Ishibashi T, Yamashita H, Kanno K, Sato S, Kiyono T and Kyo S:
Development of low-grade serous ovarian carcinoma from benign
ovarian serous cystadenoma cells. Cancers. 14(1506)2022.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Di Lorenzo P, Conteduca V, Scarpi E,
Adorni M, Multinu F, Garbi A, Betella I, Grassi T, Bianchi T, Di
Martino G, et al: Advanced low grade serous ovarian cancer: A
retrospective analysis of surgical and chemotherapeutic management
in two high volume oncological centers. Front Oncol.
12(970918)2022.PubMed/NCBI View Article : Google Scholar
|
|
17
|
De Leo A, Santini D, Ceccarelli C,
Santandrea G, Palicelli A, Acquaviva G, Chiarucci F, Rosini F,
Ravegnini G, Pession A, et al: What is new on ovarian carcinoma:
Integrated morphologic and molecular analysis following the new
2020 world health organization classification of female genital
tumors. Diagnostics (Basel). 11(697)2021.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Hollis RL, Thomson JP, van Baal J,
Ilenkovan N, Churchman M, van de Vijver K, Dijk F, Meynert AM,
Bartos C, Rye T, et al: Distinct histopathological features are
associated with molecular subtypes and outcome in low grade serous
ovarian carcinoma. Sci Rep. 13(7681)2023.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Romero I, Leskelä S, Mies BP, Velasco AP
and Palacios J: Morphological and molecular heterogeneity of
epithelial ovarian cancer: Therapeutic implications. EJC. 15:1–15.
2020.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Yu H, Wang J, Wu B, li J and Chen R:
Prognostic significance and risk factors for pelvic and para-aortic
lymph node metastasis in type I and II ovarian cancer: A large
population-based database analysis. J Ovarian Res.
16(28)2023.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Timofeeva AV, Asaturova AV, Sannikova MV,
Khabas GN, Chagovets VV, Fedorov IS, Frankevich VE and Sukhikh GT:
Search for new participants in the pathogenesis of high-grade
serous ovarian cancer with the potential to be used as diagnostic
molecules. Life (Basel). 12(2017)2022.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Wang Y, Duval AJ, Adli M and Matei D:
Biology-driven therapy advances in high-grade serous ovarian
cancer. J Clin Invest. 134(e174013)2024.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Zhang S, Dolgalev I, Zhang T, Ran H,
Levine DA and Neel BG: Both fallopian tube and ovarian surface
epithelium are cells-of-origin for high-grade serous ovarian
carcinoma. Nat Commun. 10(5367)2019.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Bischof K, Knappskog S, Hjelle SM,
Stefansson I, Woie K, Salvesen HB, Gjertsen BT and Bjorge L:
Influence of p53 isoform expression on survival in high-grade
serous ovarian cancers. Sci Rep. 9(5244)2019.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Kim YM, Lee SW, Lee YJ, Lee HY, Lee JE and
Choi EK: Prospective study of the efficacy and utility of TP53
mutations in circulating tumor DNA as a non-invasive biomarker of
treatment response monitoring in patients with high-grade serous
ovarian carcinoma. J Gynecol Oncol. 30(e32)2019.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Tuna M, Ju Z, Yoshihara K, Amos CI, Tanyi
JL and Mills GB: Clinical relevance of TP53 hotspot mutations in
high-grade serous ovarian cancers. Br J Cancer. 122:405–412.
2020.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Vitale SR, Groenendijk FH, van Marion R,
Beaufort CM, Helmijr JC, Dubbink HJ, Dinjens WNM, Ewing-Graham PC,
Smolders R, van Doorn HC, et al: TP53 mutations in serum
circulating cell-free tumor DNA as longitudinal biomarker for
high-grade serous ovarian cancer. Biomolecules.
10(415)2020.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Sriramulu S, Sun XF, Malayaperumal S,
Ganesan H, Zhang H, Ramachandran M, Banerjee A and Pathak S:
Emerging role and clinicopathological significance of aeg-1 in
different cancer types: A concise review. Cells.
10(1497)2021.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Yao L, Liu L, Xu W, Xi H, Lin S, Piao G,
Liu Y, Guo J and Wang X: mRNA-seq-based analysis predicts: AEG-1 is
a therapeutic target and immunotherapy biomarker for pan-cancer,
including OSCC. Front Immunol. 15(1484226)2024.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Khan M and Sarkar D: The scope of
astrocyte elevated gene-1/metadherin (AEG-1/MTDH) in cancer
clinicopathology: A review. Genes (Basel). 12(308)2021.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Ghafar MT and Soliman NA: Chapter
six-metadherin (AEG-1/MTDH/LYRIC) expression: Significance in
malignancy and crucial role in colorectal cancer. Adv Clin Chem.
106:235–280. 2022.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Chen Y, Huang S, Guo R and Chen D:
Metadherin-mediated mechanisms in human malignancies. Biomark Med.
15:1769–1783. 2021.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Liu J, Jiao X and Gao Q: Neoadjuvant
chemotherapy-related platinum resistance in ovarian cancer. Drug
Discov Today. 25:1232–1238. 2020.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Manna D and Sarkar D: Multifunctional role
of astrocyte elevated gene-1 (AEG-1) in cancer: Focus on drug
resistance. Cancers (Basel). 13(1792)2021.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Ding Q, Chen Y, Dong S, Xu X, Liu J, Song
P, Yu C and Ma Z: Astrocyte elevated gene-1 is overexpressed in
non-small-cell lung cancer and associated with increased tumour
angiogenesis. Interact Cardiovasc Thorac Surg. 26:395–401.
2018.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Li C, Liu J, Lu R, Yu G, Wang X, Zhao Y,
Song H, Lin P, Sun X, Yu X, et al: AEG -1 Overexpression: A novel
indicator for peritoneal dissemination and lymph node metastasis in
epithelial ovarian cancers. Int J Gynecol Cancer. 21:602–608.
2011.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Nowak M and Klink M: The role of
tumor-associated macrophages in the progression and chemoresistance
of ovarian cancer. Cells. 9(1299)2020.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Torkildsen CF, Thomsen LCV, Sande RK,
Krakstad C, Stefansson I, Lamark EK, Knappskog S and Bjørge L:
Molecular and phenotypic characteristics influencing the degree of
cytoreduction in high-grade serous ovarian carcinomas. Cancer Med.
12:14183–14195. 2023.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Millstein J, Budden T, Goode EL, Anglesio
MS, Talhouk A, Intermaggio MP, Leong HS, Chen S, Elatre W, Gilks B,
et al: Prognostic gene expression signature for high-grade serous
ovarian cancer. Ann Oncol. 31:1240–1250. 2020.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Voutsadakis IA: Low-grade serous ovarian
carcinoma: An evolution toward targeted therapy. Int J Gynecol
Cancer. 30:1619–1626. 2020.PubMed/NCBI View Article : Google Scholar
|
|
41
|
De Decker K, Wenzel HHB, Bart J, van der
Aa MA, Kruitwagen RFPM, Nijman HW and Kruse AJ: Stage, treatment
and survival of low-grade serous ovarian carcinoma in the
Netherlands: A nationwide study. Acta Obstet Gynecol Scand.
102:246–256. 2023.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Webb PM and Jordan SJ: Global epidemiology
of epithelial ovarian cancer. Nat Rev Clin Oncol. 21:389–400.
2024.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Wang Q, Cao SH, Li YY, Zhang JB, Yang XH
and Zhang B: Advances in precision therapy of low-grade serous
ovarian cancer: A review. Medicine (Baltimore).
103(e34306)2024.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Huang T, Townsend MK, Wentzensen N,
Trabert B, White E, Arslan AA, Weiderpass E, Buring JE, Clendenen
TV, Giles GG, et al: Reproductive and hormonal factors and risk of
ovarian cancer by tumor dominance: Results from the ovarian cancer
cohort consortium (OC3). Cancer Epidemiol Biomarkers Prev.
29:200–207. 2020.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Gaitskell K, Green J, Pirie K, Barnes I,
Hermon C, Reeves GK and Beral V: Histological subtypes of ovarian
cancer associated with parity and breastfeeding in the prospective
million women study. Int J Cancer. 142:281–289. 2018.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Sung S, Hong Y, Kim BG, Choi JY, Kim JW,
Park SY, Kim JH, Kim YM, Lee JM, Kim TJ and Park SK: Stratifying
the risk of ovarian cancer incidence by histologic subtypes in the
korean epithelial ovarian cancer study (Ko-EVE). Cancer Med.
12:8742–8753. 2023.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Flaum N, Crosbie EJ, Edmondson RJ, Smith
MJ and Evans DG: Epithelial ovarian cancer risk: A review of the
current genetic landscape. Clin Genet. 97:54–63. 2020.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Wilczyński J, Paradowska E and Wilczyński
M: High-grade serous ovarian cancer-a risk factor puzzle and
screening fugitive. Biomedicines. 12(229)2024.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Chen W, Liu H, Huang X, Qian L, Chen L,
Zhou Y, Liu Y, Liu Y, Wang Y, Zhang T, et al: A single-cell
landscape of pre- and post-menopausal high-grade serous ovarian
cancer ascites. iScience. 26(107712)2023.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Charkhchi P, Cybulski C, Gronwald J, Wong
FO, Narod SA and Akbari MR: Ca125 and ovarian cancer: A
comprehensive review. Cancers. 12:1–29. 2020.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Salminen L, Nadeem N, Jain S, Grènman S,
Carpén O, Hietanen S, Oksa S, Lamminmäki U, Pettersson K, Gidwani
K, et al: A longitudinal analysis of CA125 glycoforms in the
monitoring and follow up of high grade serous ovarian cancer.
Gynecol Oncol. 156:689–694. 2020.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Ciucci A, Zannoni GF, Buttarelli M,
Martinelli E, Mascilini F, Petrillo M, Ferrandina G, Scambia G and
Gallo D: Ovarian low and high grade serous carcinomas: Hidden
divergent features in the tumor microenvironment. Oncotarget.
7:68033–68043. 2016.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Porter JM, McFarlane I, Bartos C,
Churchman M, May J, Herrington CS, Connolly KC, Ryan NAJ and Hollis
RL: The survival benefit associated with complete macroscopic
resection in epithelial ovarian cancer is histotype specific. JNCI
Cancer Spectr. 8(pkae049)2024.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Irodi A, Rye T, Herbert K, Churchman M,
Bartos C, Mackean M, Nussey F, Herrington CS, Gourley C and Hollis
RL: Patterns of clinicopathological features and outcome in
epithelial ovarian cancer patients: 35 years of prospectively
collected data. BJOG. 127:1409–1420. 2020.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Chibaya L, Karim B, Zhang H and Jones SN:
Mdm2 phosphorylation by Akt regulates the p53 response to oxidative
stress to promote cell proliferation and tumorigenesis. Proc Natl
Acad Sci USA. 118(e2003193118)2021.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Wei C, Du J, Shen Y, Wang Z, Lin Q, Chen
J, Zhang F, Lin W, Wang Z, Yang Z and Ma W: Anticancer effect of
involucrasin A on colorectal cancer cells by modulating the
Akt/MDM2/p53 pathway. Oncol Lett. 25(218)2023.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Umapathy D, Karthikeyan MC, Ponnuchamy K,
Kannan MK, Ganeshan M and Arockiam AJV: The absence of cellular
glucose triggers oncogene AEG-1 that instigates VEGFC in HCC: A
possible genetic root cause of angiogenesis. Gene.
826(146446)2022.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Zhao T, Zhao C, Zhou Y, Zheng J, Gao S and
Lu Y: HIF-1α binding to AEG-1 promoter induced upregulated AEG-1
expression associated with metastasis in ovarian cancer. Cancer
Med. 6:1072–1081. 2017.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Rajesh Y, Reghupaty SC, Mendoza RG, Manna
D, Banerjee I, Subler MA, Weldon K, Lai Z, Giashuddin S, Fisher PB,
et al: Dissecting the balance between metabolic and oncogenic
functions of astrocyte-elevated gene-1/metadherin. Hepatol Commun.
6:561–575. 2022.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Rong C, Shi Y, Huang J, Wang X, Shimizu R,
Mori Y, Murai A and Liang J: The effect of metadherin on NF-κB
activation and downstream genes in ovarian cancer. Cell Transpl.
29(0963689720905506)2020.PubMed/NCBI View Article : Google Scholar
|
